Ambulatory AMI Focus TherOx specializes in improving treatment of acute myocardial infarction (AMI) with SSO2 Therapy, presenting a clear opportunity to partner with hospitals aggressively pursuing AMI outcomes and heart muscle preservation.

Strategic Acquisition As a part of ZOLL Medical Corporation since 2019, TherOx gains access to ZOLL’s broad distribution, customer base, and sales channels, enabling accelerated adoption of SSO2 Therapy through existing customer relationships and cross-selling opportunities.

PCI Postcare Tie-in TherOx SSO2 Therapy is delivered immediately after PCI, suggesting sales opportunities with interventional cardiology programs and cath labs that perform recent revascularizations, especially for anterior AMI cases treated with PCI.

Regulatory & Guidelines Alignment TherOx’s therapy aligns with current interventional cardiology guidelines for post-PCI care, which can be emphasized in conversations with hospital committees, procurement, and clinical leadership seeking guideline-consistent innovations to improve infarct size and patient outcomes.

Revenue/Market Positioning Annual revenue range indicates a growing but mid-sized footprint; focus sales strategies on mid-to-large hospitals and health systems with AMI burden and a willingness to adopt advanced therapies, leveraging ZOLL’s scale to access these accounts.